MedTrace Logo

Combination Chemotherapy in Treating Women With Breast Cancer Who Have Undergone Surgery

NCT00039546 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2013-08-07

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective in treating women after surgery for breast cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of paclitaxel, epirubicin, and cyclophosphamide with or without gemcitabine in treating women who have undergone surgery for breast cancer.

Conditions

Interventions

DRUG

cyclophosphamide

DRUG

epirubicin hydrochloride

DRUG

gemcitabine hydrochloride

DRUG

paclitaxel

PROCEDURE

adjuvant therapy

Sponsors & Collaborators

  • Cancer Research Campaign Clinical Trials Centre

    lead OTHER

Principal Investigators

  • Helen Howard, PhD · Cancer Research Campaign Clinical Trials Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00039546 on ClinicalTrials.gov